ArticleNPJ cardiovascular health2025
BAG3 concentrations and heart failure events among individuals undergoing coronary and peripheral angiography.
Article in NPJ cardiovascular health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Letter regarding: "A systematic review of GWAS on CMR imaging traits: genetic insights into cardiovascular structure, function, and diseases".EBioMedicine · 2026Article
- BAG3 in human tumors.Frontiers in oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
To investigate the circulating BAG3 role as a biomarker across Universal Definition of Heart Failure (UDHF) stages, plasma samples from 1121 individuals undergoing coronary and/or peripheral angiography across UDHF stages were analyzed using a novel BAG3 assay. In the whole sample, higher BAG3 concentrations predicted CV death (HR = 1.18; p = 0.001) and the composite endpoint MACE (Major Adverse Cardiovascular Events) (HR = 1.12; p = 0.006). In patients in the asymptomatic A and B stages, higher BAG3 concentrations predicted the onset of the first symptomatic HF event and the total burden of subsequent HF events (HR = 1.13; p = 0.05). The prognostic value of circulating BAG3 since the HF asymptomatic phases suggests its potential functional role in the disease and the possible utility of its measurement for risk stratification and management of cardiovascular diseases.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.